β-Catenin/TCF4 Is Required for DDX17-Induced Epithelial-Mesenchymal Transition and Metastasis in Hepatocellular Carcinoma

Abstract

The DEAD-box RNA helicase 17 (DDX17) is strongly linked to the occurrence and development of specific human cancers, emphasizing its previously unrecognized biological roles in cancer progression and metastasis. However, the precise mechanisms by which DDX17 regulates liver cancer metastasis have not been thoroughly explored. In this study, increased DDX17 expression levels showed a robust association with the invasive potential of hepatocellular carcinoma (HCC) cells. Silencing DDX17 expression resulted in substantial reduction of HCC cell migration and invasion potentials, while DDX17 overexpression had the opposite effect. Silencing DDX17 also attenuated epithelial-mesenchymal transition (EMT) in HCC cells and significantly reduced metastatic lesions in an orthotopic HCC nude mouse model. Mechanistically, chromatin immunoprecipitation assays revealed that TCF4 physically interacts with the DDX17 promoter, activating its transcriptional expression. Immunoprecipitation results demonstrated that DDX17-mediated nuclear input of β-catenin is dependent on its helicase functional domain. Furthermore, we demonstrated that β-catenin/TCF4 is essential for DDX17-induced migration and invasion in HCC cells. Taken together, these findings emphasize the significance of DDX17 in the malignant progression and metastasis of HCC, revealing a novel mechanism involving the β-catenin/TCF4/DDX17 pathway.

Keywords

β-catenin/TCF4 signaling / epithelial-mesenchymal transition / liver cancer / RNA helicase

References

[1] X. Liao, Y. Bu, and Q. Jia, “Traditional Chinese Medicine as Supportive Care for the Management of Liver Cancer: Past, Present, and Future,” Genes & Diseases 7, no. 3 (2020): 370-379.

[2] S. Cernea and D. Onișor, “Screening and Interventions to Prevent Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis-Associated Hepatocellular Carcinoma,” World Journal of Gastroenterology 29, no. 2 (2023): 286-309.

[3] D. Wang, M. Xiao, Z. M. Wan, X. Lin, Q. Y. Li, and S. S. Zheng, “Surgical Treatment for Recurrent Hepatocellular Carcinoma: Current Status and Challenges,” World Journal of Gastrointestinal Surgery 15, no. 4 (2023): 544-552.

[4] H. Rumgay, M. Arnold, J. Ferlay, et al., “Global Burden of Primary Liver Cancer in 2020 and Predictions to 2040,” Journal of Hepatology 77, no. 6 (2022): 1598-1606.

[5] V. Mazzaferro, C. Sposito, J. Zhou, et al., “Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma,” Gastroenterology 154, no. 1 (2018): 128-139.

[6] Z. J. Brown, D. I. Tsilimigras, S. M. Ruff, et al., “Management of Hepatocellular Carcinoma: A Review,” JAMA Surgery 158, no. 4 (2023): 410-420.

[7] A. Dongre and R. A. Weinberg, “New Insights Into the Mechanisms of Epithelial-Mesenchymal Transition and Implications for Cancer,” Nature Reviews Molecular Cell Biology 20, no. 2 (2019): 69-84.

[8] Y. Huang, W. Hong, and X. Wei, “The Molecular Mechanisms and Therapeutic Strategies of EMT in Tumor Progression and Metastasis,” Journal of Hematology & Oncology 15, no. 1 (2022): 129.

[9] B. Du and J. Shim, “Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer,” Molecules 21, no. 7 (2016): 965.

[10] V. Mittal, “Epithelial Mesenchymal Transition in Tumor Metastasis,” Annual Review of Pathology: Mechanisms of Disease 13 (2018): 395-412.

[11] R. Huang and X. Zong, “Aberrant Cancer Metabolism in Epithelial-Mesenchymal Transition and Cancer Metastasis: Mechanisms in Cancer Progression,” Critical Reviews in Oncology/Hematology 115 (2017): 13-22.

[12] F. V. Fuller-Pace and H. C. Moore, “RNA Helicases p68 and p72: Multifunctional Proteins With Important Implications for Cancer Development,” Future Oncology 7, no. 2 (2011): 239-251.

[13] G. Zhao, Q. Wang, Y. Zhang, et al., “DDX17 Induces Epithelial-Mesenchymal Transition and Metastasis Through the miR-149-3p/CYBRD1 Pathway in Colorectal Cancer,” Cell Death & Disease 14, no. 1 (2023): 1.

[14] X. Liu, L. Li, C. Geng, et al., “DDX17 Promotes the Growth and Metastasis of Lung Adenocarcinoma,” Cell Death Discovery 8, no. 1 (2022): 425.

[15] S. Shin, K. L. Rossow, J. P. Grande, and R. Janknecht, “Involvement of RNA Helicases p68 and p72 in Colon Cancer,” Cancer Research 67, no. 16 (2007): 7572-7578.

[16] X. N. Li, Z. J. Wang, C. X. Ye, B. C. Zhao, Z. L. Li, and Y. Yang, “RNA Sequencing Reveals the Expression Profiles of CircRNA and Indicates That circDDX17 Acts as a Tumor Suppressor in Colorectal Cancer,” Journal of Experimental & Clinical Cancer Research 37, no. 1 (2018): 325.

[17] H. Z. Zhou, F. Li, S. T. Cheng, et al., “DDX17-Regulated Alternative Splicing That Produced an Oncogenic Isoform of PXN-AS1 to Promote HCC Metastasis,” Hepatology 75, no. 4 (2022): 847-865.

[18] C. He, G. Zhang, Y. Lu, J. Zhou, and Z. Ren, “DDX17 Modulates the Expression and Alternative Splicing of Genes Involved in Apoptosis and Proliferation in Lung Adenocarcinoma Cells,” PeerJ 10 (2022): e13895.

[19] D. Hanahan, “Hallmarks of Cancer: New Dimensions,” Cancer Discovery 12, no. 1 (2022): 31-46.

[20] G. Pan, Y. Liu, L. Shang, F. Zhou, and S. Yang, “EMT-Associated Micrornas and Their Roles in Cancer Stemness and Drug Resistance,” Cancer Communications 41, no. 3 (2021): 199-217.

[21] Y. Xue, X. Jia, C. Li, et al., “DDX17 Promotes Hepatocellular Carcinoma Progression via Inhibiting Klf4 Transcriptional Activity,” Cell Death & Disease 10, no. 11 (2019): 814.

[22] X. C. Wu, W. G. Yan, Z. G. Ji, G. Y. Zheng, and G. H. Liu, “Long Noncoding RNA SNHG20 Promotes Prostate Cancer Progression via Upregulating DDX17,” Archives of Medical Science 17, no. 6 (2021): 1752-1765.

[23] Y. Sun, C. Zhang, Q. Fang, W. Zhang, and W. Liu, “Abnormal Signal Pathways and Tumor Heterogeneity in Osteosarcoma,” Journal of Translational Medicine 21, no. 1 (2023): 99.

[24] C. C. Liu, D. L. Cai, F. Sun, et al., “FERMT1 Mediates Epithelial-Mesenchymal Transition to Promote Colon Cancer Metastasis via Modulation of β-Catenin Transcriptional Activity,” Oncogene 36, no. 13 (2017): 1779-1792.

[25] S. Yang, Y. Liu, M. Y. Li, et al., “FOXP3 Promotes Tumor Growth and Metastasis by Activating Wnt/β-Catenin Signaling Pathway and EMT in Non-Small Cell Lung Cancer,” Molecular Cancer 16, no. 1 (2017): 124.

[26] S. H. Shin, D. Y. Lim, K. Reddy, et al., “A Small Molecule Inhibitor of the β-Catenin-TCF4 Interaction Suppresses Colorectal Cancer Growth In Vitro and In Vivo,” EBioMedicine 25 (2017): 22-31.

[27] W. Wang, M. Yi, S. Chen, et al., “NOR1 Suppresses Cancer Stem-Like Cells Properties of Tumor Cells via the Inhibition of the AKT-GSK-3β-Wnt/β-Catenin-ALDH1A1 Signal Circuit,” Journal of Cellular Physiology 232, no. 10 (2017): 2829-2840.

[28] E. Van Aken, O. De Wever, C. A. da Rocha, and M. Mareel, “Defective E-Cadherin/Catenin Complexes in Human Cancer,” Virchows Archiv 439, no. 6 (2001): 725-751.

[29] J. Bian, M. Dannappel, C. Wan, and R. Firestein, “Transcriptional Regulation of Wnt/β-Catenin Pathway in Colorectal Cancer,” Cells 9, no. 9 (2020): 2125.

[30] Y. He, X. Jiang, L. Duan, et al., “LncRNA PKMYT1AR Promotes Cancer Stem Cell Maintenance in Non-Small Cell Lung Cancer via Activating Wnt Signaling Pathway,” Molecular Cancer 20, no. 1 (2021): 156.

[31] J. Jin, P. Zhan, M. Katoh, et al., “Prognostic Significance of β-Catenin Expression in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis,” Translational Lung Cancer Research 6, no. 1 (2017): 97-108.

[32] N. Ghosh, U. Hossain, A. Mandal, and P. C. Sil, “The Wnt Signaling Pathway: A Potential Therapeutic Target Against Cancer,” Annals of the New York Academy of Sciences 1443, no. 1 (2019): 54-74.

[33] D. F. Quail and J. A. Joyce, “Microenvironmental Regulation of Tumor Progression and Metastasis,” Nature Medicine 19, no. 11 (2013): 1423-1437.

[34] H. J. Chen, L. S. Hsu, Y. T. Shia, M. W. Lin, and C. M. Lin, “The β-catenin/TCF Complex as a Novel Target of Resveratrol in the Wnt/β-catenin Signaling Pathway,” Biochemical Pharmacology 84, no. 9 (2012): 1143-1153.

[35] W. Zhao, J. Zhou, Z. Deng, Y. Gao, and Y. Cheng, “Spop Promotes Tumor Progression via Activation of β-Catenin/TCF4 Complex in Clear Cell Renal Cell Carcinoma,” International Journal of Oncology 49, no. 3 (2016): 1001-1008.

[36] E. Sánchez-Tilló, O. de Barrios, L. Siles, M. Cuatrecasas, A. Castells, and A. Postigo, “β-Catenin/TCF4 Complex Induces the Epithelial-to-Mesenchymal Transition (EMT)-Activator ZEB1 to Regulate Tumor Invasiveness,” Proceedings of the National Academy of Sciences 108, no. 48 (2011): 19204-19209.

[37] C. Lv, Y. Li, T. Wang, et al., “Taurolidine Improved Protection Against Highly Pathogenetic Avian Influenza H5N1 Virus Lethal-Infection in Mouse Model by Regulating the NF-κB Signaling Pathway,” Virologica Sinica 38, no. 1 (2023): 119-127.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm - Oncology published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).